Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Abroad (travel likely)RecruitingPHASE2

Conditions

Nasopharyngeal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Stanford University, Palo Alto, California, United States
Contact: Study coordinator (Elizabeth Winters) · ewinters@stanford.edu · 650-723-6372
Contact: Principal Investigator (A. Dimitrios Colevas, MD)

Study leads

A. Dimitrios Colevas, MD
Principal Investigator
Stanford University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma · High-Risk Cancer · Maintenance Therapy

Abroad (travel likely)RecruitingPHASE3

Ganzhou, China · Guangzhou, China

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma · PD-1 · Surgery

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China · Guangzhou, China

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma · Hypopharyngeal Squamous Cell Carcinoma · Laryngeal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Irvine, United States · Orange, United States

CD70-targeted immunoPET Imaging of Malignant Cancers

Renal Cancer · Renal Clear Cell Carcinoma · Lymphoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China